• Measure Summary
  • NQMC:007191
  • 2009 Nov

Melanoma: percentage of patients with a melanoma less than or equal to 1 mm thick (i.e., T1) for whom the surgical excision margins are 1 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

  • Measure Summary
  • NQMC:007188
  • 2009 Nov

Melanoma: percentage of patients with a melanoma in situ (i.e., Tis) for whom the surgical excision margins are 5 mm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

  • Measure Summary
  • NQMC:007194
  • 2009 Nov

Melanoma: percentage of patients to undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom lymphoscintigraphy is performed to identify the draining nodal basin(s) when drainage to more than one basin is possible.

American College of Surgeons

  • Measure Summary
  • NQMC:007200
  • 2009 Nov

Melanoma: percentage of patients who undergo an axillary lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 10 regional lymph nodes are resected and pathologically examined.

American College of Surgeons

  • Measure Summary
  • NQMC:007197
  • 2009 Nov

Melanoma: percentage of patients who have a stage Ib or II melanoma with whom sentinel lymph node biopsy (SLNB) is discussed.

American College of Surgeons

  • Measure Summary
  • NQMC:007206
  • 2009 Nov

Melanoma: percentage of patients who have a resected primary melanoma metastatic to regional lymph nodes or distant sites for whom there is a documented discussion regarding adjuvant therapy.

American College of Surgeons

  • Measure Summary
  • NQMC:007189
  • 2009 Nov

Melanoma: percentage of patients with a melanoma for whom the surgeon documented the measured surgical margin in the operative report.

American College of Surgeons

  • Measure Summary
  • NQMC:007209
  • 2009 Nov

Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

American College of Surgeons

  • Measure Summary
  • NQMC:007195
  • 2009 Nov

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are sent for permanent sectioning only (no frozen sections), unless a reason is documented.

American College of Surgeons

  • Measure Summary
  • NQMC:007192
  • 2009 Nov

Melanoma: percentage of patients with a melanoma 1-2 mm thick (i.e., T2) for whom the surgical excision margins are 1-2 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

  • Measure Summary
  • NQMC:007204
  • 2009 Nov

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma for whom the pathology report documents the number of lymph nodes examined and the number of lymph nodes found to contain metastases.

American College of Surgeons

  • Measure Summary
  • NQMC:007201
  • 2009 Nov

Melanoma: percentage of patients who undergo an inguinal lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least five regional lymph nodes are resected and pathologically examined.

American College of Surgeons

  • Measure Summary
  • NQMC:007198
  • 2009 Nov

Melanoma: percentage of patients with melanoma and clinically apparent/palpable lymphadenopathy for whom a lymph node dissection (LND) is performed without an antecedent histologic diagnosis.

American College of Surgeons

  • Measure Summary
  • NQMC:007187
  • 2009 Nov

Melanoma: is the surgeon who performs sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma certified by the American Board of Surgery or equivalent board or international association?

American College of Surgeons

  • Measure Summary
  • NQMC:007207
  • 2009 Nov

Melanoma: percentage of patients who have stages 0, I, or IIA melanoma for whom an abdominal CT/MRI, pelvic CT/MRI, or PET scan was not performed, except in response to specific signs or symptoms.

American College of Surgeons

  • Measure Summary
  • NQMC:007190
  • 2009 Nov

Melanoma: percentage of patients with a melanoma for whom a clear histologic margin is documented.

American College of Surgeons

  • Measure Summary
  • NQMC:007210
  • 2009 Nov

Melanoma: percentage of patients with melanoma who have a metastatic lymph node detected on sentinel lymph node biopsy (SLNB) for whom a complete lymph node dissection (CLND) is performed except in the context of a clinical trial or if the patient has severe comorbidities.

American College of Surgeons

  • Measure Summary
  • NQMC:007193
  • 2009 Nov

Melanoma: percentage of patients with a melanoma greater than or equal to 2 mm thick (i.e., T3 or T4) for whom the surgical excision margins are 2-3 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

  • Measure Summary
  • NQMC:007199
  • 2009 Nov

Melanoma: percentage of patients who undergo a cervical lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 15 regional lymph nodes are resected and pathologically examined.

American College of Surgeons

  • Measure Summary
  • NQMC:007202
  • 2009 Nov

Melanoma: percentage of patients with a melanoma for whom the pathology report documents Breslow thickness, Clark level, histologic ulceration, peripheral/radial and deep margin statuses, satellitosis, anatomic location of the lesion, regression, and mitotic rate.

American College of Surgeons